# A Study to Assess the Safety, Tolerability, Ciliary Rescue, and Pharmacodynamics of RCT1100 in Adults With PCD

> **NCT06600425** · PHASE1 · COMPLETED · sponsor: **ReCode Therapeutics** · enrollment: 7 (actual)

## Conditions studied

- Primary Ciliary Dyskinesia

## Interventions

- **DRUG:** RCT1100

## Key facts

- **NCT ID:** NCT06600425
- **Lead sponsor:** ReCode Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-09-20
- **Primary completion:** 2025-06-06
- **Final completion:** 2025-08-27
- **Target enrollment:** 7 (ACTUAL)
- **Last updated:** 2025-10-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06600425

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06600425, "A Study to Assess the Safety, Tolerability, Ciliary Rescue, and Pharmacodynamics of RCT1100 in Adults With PCD". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT06600425. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*